New Alzheimer's drug SHR-1707 passes early safety check in 33 patients
NCT ID NCT05681819
First seen May 11, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This early-stage study tested a new drug called SHR-1707 in 33 people with mild Alzheimer's disease or mild cognitive impairment. The main goal was to see if the drug is safe and how the body processes it. Researchers also looked at whether it could reduce amyloid plaques in the brain, a hallmark of Alzheimer's.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital Of USTC
Hefei, Anhui, 230001, China
Conditions
Explore the condition pages connected to this study.